AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in rat models of nociceptive pain

References

• Poole AR, Rizkalla G, Ionescu M, Reiner A, Brooks E, Rorabeck C, et al. Osteoarthritis in the human knee: a dynamic process of cartilage matrix degradation, synthesis and reorganisation. Agents Actions Suppl. 1993;39:3–13.
   PubMedGoogle Scholar
• Briggs A, Scott E, Steele K. Impact of osteoarthritis and analgesic treatment on quality of life of an elderly population. Ann Pharmacother. 1999;33(11):1154–9.
   PubMed Web of Science ®Google Scholar
• Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME. Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. J Rheumatol. 2001;28(6):1330–7.
   PubMed Web of Science ®Google Scholar
• Bjordal JM, Ljunggren AE, Klovning K, Slørdal L. Non-steroidal antiinflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ. 2004;329(7478):1317–20.
   PubMedGoogle Scholar
• Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum. 2003;48(8):2173–7.
   PubMedGoogle Scholar
• Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008;9:116.
   PubMed Web of Science ®Google Scholar
• Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 2001;134(7):541–9.
   PubMed Web of Science ®Google Scholar
• Neugebauer V, Han JS, Adwanikar H, Fu Y, Ji G. Techniques for assessing knee joint pain in arthritis. Mol Pain. 2007;3:8.
   PubMed Web of Science ®Google Scholar
• Yoshimi E, Kumakura F, Hatori C, Hamachi E, Iwashita A, Ishii N, et al. Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis. J Pharmacol Exp Ther. 2010;334(3):955–63.
   PubMed Web of Science ®Google Scholar
• Meini S, Maggi CA. Knee osteoarthritis: a role for bradykinin? Inflamm Res. 2008;57(8):351–61.
   PubMed Web of Science ®Google Scholar
• Gotoh S, Miyazaki K, Onaya J, Sakamoto T, Tokuyasu K, Namiki O. Experimental knee pain model in rats and analgesic effect of sodium hyaluronate (SPH). Nihon Yakurigaku Zasshi. 1988;92(1):17–27.
   PubMed Web of Science ®Google Scholar
• Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, et al. Pain related behavior in two models of osteoarthritis in the rat knee. Pain. 2004;112(1–2):83–93.
   PubMed Web of Science ®Google Scholar
• Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003;11(11):821–30.
   PubMed Web of Science ®Google Scholar
• Thor K, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract. 2007;61(8):1349–55.
   PubMed Web of Science ®Google Scholar
• Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2010;11(1):33–41.
   Web of Science ®Google Scholar
• Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther. 2005;312(2):726–32.
   PubMed Web of Science ®Google Scholar
• Yamamoto M. Pharmacological and biochemical properties of indeloxazine hydrochloride, a new cerebral activator. Brain Dysfunct. 1990;3:130–47.
   Google Scholar
• Shimizu-sasamata M, Yamamoto M, Harada M. Central activating properties of indeloxazine HCl and its optical isomers. Pharmacol Biochem Behav. 1993;45(2):335–41.
   PubMed Web of Science ®Google Scholar
• Murai N, Aoki T, Tamura S, Sekizawa T, Kakimoto S, Tsukamoto M, et al. AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in a rat model of neuropathic pain with unique characteristics in spinal monoamine turnover. J Pharmacol Exp Ther. 2014;348(3):372–82.
   PubMed Web of Science ®Google Scholar
• Murai N, Tsukamoto M, Tamura S, Aoki T, Matsuoka N. Antinociceptive effects of AS1069562, the (+)-isomer of indeloxazine, on spinal hypersensitivity induced by intrathecal injection of prostaglandin in mice: comparison with duloxetine and amitriptyline. Eur J Pharmacol. 2014;733:54–61.
   PubMed Web of Science ®Google Scholar
• Murai N, Aoki T, Tamura S, Yamamoto H, Hamakawa N, Matsuoka N. AS1069562, the (+)-isomer of indeloxazine, but not duloxetine has a curative-like analgesic effect in a rat model of streptozotocin-induced diabetic neuropathy. Neuropharmacology. 2014;79:10–6.
   PubMed Web of Science ®Google Scholar
• Colpaert FC, Wu WP, Hao JX, Royer I, Sautel F, Wiesenfeld-Hallin Z, et al. High-efficacy 5-HT1A receptor activation causes a curative-like action on allodynia in rats with spinal cord injury. Eur J Pharmacol. 2004;497(1):29–33.
   PubMed Web of Science ®Google Scholar
• Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther. 2007;113(1):134–53.
   PubMed Web of Science ®Google Scholar